Abstract
CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.
| Original language | English |
|---|---|
| Pages (from-to) | 988-993 |
| Number of pages | 6 |
| Journal | British Journal of Haematology |
| Volume | 198 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2022 Sept |
Bibliographical note
Funding Information:The authors thank Erin P. O'Keefe, PhD, and Lisa R. Denny, PhD (ICON, Blue Bell, PA), whose work was funded by Amgen Inc., for medical writing assistance in the preparation of this manuscript. Dr Landgren thanks Sylvester Comprehensive Cancer Center Core Grant (P30 CA240139) for support. He also thanks Paula and Rodger Riney Foundation for generous support of his research program.
Funding Information:
reports honoraria and/or membership on the board of directors for Adaptive, Amgen, Celgene, Janssen, and Takeda; membership on independent data monitoring committees for Merck and Theradex. reports consultancy for Janssen, Adaptive Biotech, Amgen, Bristol Myers Squibb, Sanofi, Takeda, Oncopeptides, Karyopharm, GlaxoSmithKline, and Celgene; honoraria from Janssen, Adaptive Biotech, Amgen, Bristol Myers Squibb, Celgene, Sanofi, Takeda, and GlaxoSmithKline; grants or contracts (to institution) from Janssen, Amgen, Celgene, and Sanofi. reports honoraria from Janssen, Celgene, Amgen, Takeda, Sanofi, and GlaxoSmithKline. reports consultancy with Takeda, AbbVie, Amgen, Janssen, Celgene, Sanofi; honoraria from Takeda, AbbVie, Amgen, GlaxoSmithKline, Janssen, Celgene; travel accommodations/expenses with Takeda and AbbVie; research funding from AbbVie, GlaxoSmithKline, Sanofi; membership on Board of Directors or advisory committee with Celgene. has no relevant financial relationships to disclose. reports consultancy with PharmaMar, Takeda, AbbVie, Oncopeptides, Novartis, Janssen, Amgen, and Bristol Myers Squibb; honoraria with PharmaMar, Takeda, AbbVie, Janssen, Amgen, and Bristol Myers Squibb; membership on Board of Directors or advisory committees with Takeda and Amgen; research funding from Takeda, Novartis, Janssen, Amgen, and Bristol Myers Squibb. reports membership on Board of Directors or advisory committees with Janssen, Bristol Myers Squibb/Celgene, Amgen, Takeda, Pfizer, Caelum; research funding with Janssen. reports honoraria and research funding from Alexion Pharmaceuticals Inc. reports employment with Parexel International. and report employment with and stockholdings of Amgen. reports grants and personal fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, Merck, and GlaxoSmithKline; personal fees from AbbVie, MundiPharma, SecuraBio, Gilead, Genentech, and Oncopeptides; grants from Bristol Myers Squibb and Pharmacyclics. OL KW LR CT MT RH PM JSK NS XH CL SZU
Publisher Copyright:
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
All Science Journal Classification (ASJC) codes
- Hematology